Bernadine G. C. Lu

Bernadine G. C. Lu

Auto-generated profile, based on publicly available information

Bernadine G. C. Lu

The Walter and Eliza Hall Institute for Medical Research, Parkville, Australia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2020 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
TKTheresa Klemm
Theresa Klemm
GEGregor Ebert
Gregor Ebert
DCDale J Calleja
Dale J Calleja
CACody C Allison
Cody C Allison
LRLachlan W Richardson
Lachlan W Richardson
DKDavid Komander
David Komander
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

3 April 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBStefanie M. Bader
Stefanie M. Bader
DCDale J. Calleja
Dale J. Calleja
SDShane M. Devine
Shane M. Devine
NKNathan W. Kuchel
Nathan W. Kuchel
BLBernadine G. C. Lu
Bernadine G. C. Lu
DKDavid Komander
David Komander
The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 has highlighted the vulnerability of a globally connected population to zoonotic viruses. The FDA-approved coronavirus antiviral Paxlovid targets the essential SARS-CoV-2 main protease, Mpro. Whilst effective in the acute phase of a COVID infection, Paxlovid cannot be used by all patients, can lead to viral recurrence, and does not protect against post-acute sequelae of COVID-19 (PASC), commonly known as long COVID, an emerging significant health burden that remains poorly understood and untreated. Alternative antivirals that are addressing broader patient needs are urgently required. We here report our drug discovery efforts to target PLpro, a further essential coronaviral protease, for which we report a novel chemical scaffold that targets SARS-CoV-2 PLpro with low nanomolar activity, and which exhibits activity against PLpro of other pathogenic coronaviruses. Our lead compound shows excellent in vivo efficacy in a mouse model of severe acute disease. Importantly, our mouse model recapitulates long-term pathologies matching closely those seen in PASC patients. Our lead compound offers protection against a range of PASC symptoms in this model, prevents lung pathology and reduces brain dysfunction. This provides proof-of-principle that PLpro inhibition may have clinical relevance for PASC prevention and treatment going forward.

23 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
XWXinyu Wu
Xinyu Wu
MGMargareta Go
Margareta Go
JNJulie V. Nguyen
Julie V. Nguyen
NKNathan W. Kuchel
Nathan W. Kuchel
BLBernadine G. C. Lu
Bernadine G. C. Lu
MCMelissa Call
Melissa Call
Papain-like protease (PLpro) is an attractive drug target for SARS-CoV-2 because it is essential for viral replication, cleaving viral poly-proteins pp1a and pp1ab, and has de-ubiquitylation and de-ISGylation activities, affecting innate immune responses. We employ Deep Mutational Scanning to evaluate the mutational effects on PLpro enzymatic activity and protein stability in mammalian cells. We confirm features of the active site and identify mutations in neighboring residues that alter activity. We characterize residues responsible for substrate binding and demonstrate that although residues in the blocking loop are remarkably tolerant to mutation, blocking loop flexibility is important for function. We additionally find a connected network of mutations affecting activity that extends far from the active site. We leverage our library to identify drug-escape variants to a common PLpro inhibitor scaffold and predict that plasticity in both the S4 pocket and blocking loop sequence should be considered during the drug design process.

19 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
TKTheresa Klemm
Theresa Klemm
GEGregor Ebert
Gregor Ebert
DCDale J. Calleja
Dale J. Calleja
CACody C. Allison
Cody C. Allison
LRLachlan W. Richardson
Lachlan W. Richardson
DKDavid Komander
David Komander
Coronaviruses, including SARS-CoV-2, encode multifunctional proteases that are essential for viral replication and evasion of host innate immune mechanisms. The papain-like protease PLpro cleaves the viral polyprotein, and reverses inflammatory ubiquitin and anti-viral ubiquitin-like ISG15 protein modifications 1,2 . Drugs that target SARS-CoV-2 PLpro (hereafter, SARS2 PLpro) may hence be effective as treatments or prophylaxis for COVID-19, reducing viral load and reinstating innate immune responses 3 . We here characterise SARS2 PLpro in molecular and biochemical detail. SARS2 PLpro cleaves Lys48-linked polyubiquitin and ISG15 modifications with high activity. Structures of PLpro bound to ubiquitin and ISG15 reveal that the S1 ubiquitin binding site is responsible for high ISG15 activity, while the S2 binding site provides Lys48 chain specificity and cleavage efficiency. We further exploit two strategies to target PLpro. A repurposing approach, screening 3727 unique approved drugs and clinical compounds against SARS2 PLpro, identified no compounds that inhibited PLpro consistently or that could be validated in counterscreens. More promisingly, non-covalent small molecule SARS PLpro inhibitors were able to inhibit SARS2 PLpro with high potency and excellent antiviral activity in SARS-CoV-2 infection models.

7 April 2026 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
PSPhilipp Schenk
Philipp Schenk
SDShane M Devine
Shane M Devine
SCSimon Cobbold
Simon Cobbold
NGNiall D Geoghegan
Niall D Geoghegan
EKElizabeth L Kyran
Elizabeth L Kyran
DKDavid Komander
David Komander
The ubiquitin-specific protease (USP) USP9X is a human deubiquitinase (DUB) with a large number of described targets and cellular roles. In cancer, USP9X is found as an oncogene or as a tumour suppressor depending on context, and its utility as a target for cancer therapy remains unclear. We here describe WEHI-092, a piperazine-based USP9X-specific small-molecule inhibitor, which binds to a unique region in the USP9X Fingers-subdomain, distinct from known DUB-inhibitor binding sites. Using proteomics and ubiquitinomics, we show that USP9X targets distinct substrates compared to USP7, yet the substrate profile of USP9X varies significantly across cancer cell lines. We reveal a core set of 17 proteins commonly regulated by USP9X in most cell lines, which we consider as proximal biomarkers for USP9X inhibition. Consistent with proteomics, we show in unrelated cell lines that WEHI-092 treatment arrests the cell cycle in metaphase without inducing cell death. This explains growth suppression in long-term clonogenic assays in most cancer cell lines, and positions USP9X inhibitors as a new class of selective mitotic poisons.

12 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
XWXinyu Wu
Xinyu Wu
MGMargareta Go
Margareta Go
JNJulie V. Nguyen
Julie V. Nguyen
NKNathan W. Kuchel
Nathan W. Kuchel
BLBernadine G.C. Lu
Bernadine G.C. Lu
MCMelissa Call
Melissa Call
SARS-CoV-2, the causative agent of COVID-19, is responsible for the recent global pandemic and remains a major source of mortality. Papain-like protease (PLpro) is a target for SARS-CoV-2 inhibitor development, as it is not only essential for viral replication through cleavage of the viral poly-proteins pp1a and pp1ab, but also has de-ubiquitylation and de-ISGylation activities, which can affect innate immune responses. To understand the features of PLpro that dictate activity and anticipate how emerging PLpro variants will affect function, we employed Deep Mutational Scanning to evaluate the mutational effects on enzymatic activity and protein stability in mammalian cells. We confirm features of the active site and identify all mutations in neighboring residues that support or ablate activity. We characterize residues responsible for substrate binding and demonstrate that although the blocking loop is remarkably tolerant to nearly all mutations, its flexibility is important for enzymatic function. We additionally find a connected network of mutations affecting function but not structure that extends far from the active site. Using our DMS libraries we were able to identify drug-escape variants to a common PLpro inhibitor scaffold and predict that plasticity in both the S4 pocket and blocking loop sequence should be considered during the drug design process.